



**Alliance Capital Partners Limited**  
**同人融資有限公司**

**STRICTLY CONFIDENTIAL**

28 January 2025

The Board of Directors,  
**China NT Pharma Group Company Limited**  
Suite 3613  
36/F Cosco Tower  
183 Queen's Road Central  
Hong Kong

Dear Sirs,

**Re: (1) Connected transaction in relation to loan capitalization involving  
subscription of shares under specific mandate; and  
(2) Application for whitewash waiver (collectively the "Transactions")**

We, Alliance Capital Partners Limited, refer to the circular (the "**Circular**") dated 28 January 2025 in respect of the Transactions. Unless the context otherwise requires, terms used below shall have the same meanings as those defined in the Circular.

We hereby give, and have not withdrawn, our consent to the issue of the Circular with the inclusion therein of our name, our opinions and all references thereto in the form and context in which they respectively appear in the Circular.

Furthermore, we hereby give, and have not withdrawn, our consent to this letter being made available for inspection as described in the Circular.

As at the Latest Practicable Date, we did not have any direct or indirect shareholding in any member of the Group, or any right to subscribe for or to nominate persons to subscribe for securities in any member of the Group, or any interests, directly or indirectly, in any asset which had been acquired, disposed of by or leased to any member of the Group, or was proposed to be acquired, disposed of by or leased to any member of the Group, since 31 December 2023, being the date to which the latest published audited financial statements of the Group were made up.



**Alliance Capital Partners Limited**  
**同人融資有限公司**

Yours faithfully,  
For and on behalf of  
**Alliance Capital Partners Limited**

---

Alyssa Ng  
*Managing Director*